Abstract
Background The immunopathological pathways enabling post-COVID syndrome (PCS) development are not entirely known. We underwent a longitudinal analysis of patients with COVID-19 who developed PCS aiming to evaluate the autoimmune and immunological status associated with this condition.
Methods Thirty-three patients were included for longitudinal clinical and autoantibody analyses of whom 12 patients were assessed for cytokines and lymphocyte populations. Patients were followed during 7-11 months after acute COVID-19. Autoimmune profile and immunological status were evaluated mainly by enzyme-linked-immunosorbent assays and flow cytometry.
Results Latent autoimmunity and overt autoimmunity persisted over time. A proinflammatory state was observed in patients with PCS characterized by upregulated IFN-α, TNF-α, G-CSF, IL-17A, IL-6, IL-1β, and IL-13, whereas IP-10 was decreased. In addition, PCS was characterized by increased levels of Th9, CD8+ effector T cells, naive B cells, and CD4+ effector memory T cells. Total levels of IgG S1-SARS-CoV-2 antibodies remained elevated over time.
Discussion The clinical manifestations of PCS are associated with the persistence of a proinflammatory, and effector phenotype induced by SARS-CoV-2 infection. This long-term persistent immune activation may contribute to the development of latent and overt autoimmunity. Results suggest the need to evaluate the role of immunomodulation in the treatment of PCS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Universidad del Rosario grant numbers IV-FBG001, and ABN-011.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board of the CES University approved the study design.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- ACAs
- Anti-cardiolipin antibodies.
- AITD
- Autoimmune thyroid disease.
- ANAs
- Anti-nuclear antibodies.
- β2GP1
- β2 glycoprotein-1.
- CCP3
- Citrullinated peptide third generation.
- COVID-19
- Coronavirus disease 2019.
- CRP
- C reactive protein.
- dsDNA
- Double-stranded DNA.
- ELISA
- Enzyme-linked-immunosorbent assay.
- ICU
- Intensive care unit.
- IQR
- Interquartile range.
- PCA
- Principal component analysis.
- PCS
- Post-COVID syndrome.
- RF
- Rheumatoid Factor.
- RNP
- Ribonucleoprotein.
- SARS-CoV-2
- Severe acute respiratory syndrome coronavirus 2.
- Sm
- Smith.
- Tg
- Thyroglobulin.
- TPO
- Thyroid peroxidase.
